Local drug delivery of Argatroban from a polymeric-metallic composite stent reduces platelet deposition in a swine coronary model

Catheterization and Cardiovascular Interventions

Volumn 46, Issue 4, 1999, Pages 503-507

  Kruse, Kevin R ^a   Crowley, James J ^a   Tanguay, Jean Francois ^a   Santos, Renato M ^a   Millare, Debbie Sanders ^b   Phillips, Harry R ^a   Zidar, James P ^a   Stack, Richard S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b BOSTON SCIENTIFIC CORPORATION   (United States)

Author keywords

Antithrombin; PTCA; Thrombosis

Indexed keywords

ARGATROBAN; POLYCAPROLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DRUG DELIVERY SYSTEM; DRUG RELEASE; IMPLANTATION; NONHUMAN; STENT; SWINE; THROMBOCYTE AGGREGATION;

ANIMALS; ANTITHROMBINS; BLOOD PLATELETS; CORONARY THROMBOSIS; CORONARY VESSELS; INDIUM RADIOISOTOPES; METALS; PIPECOLIC ACIDS; POLYMERS; RANDOM ALLOCATION; STENTS; SWINE;

EID: 0033056775     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1522-726X(199904)46:4<503::AID-CCD25>3.0.CO;2-3     Document Type: Article

References (22)

1. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease: Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.
2. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease: Benestent Study Group. N Engl J Med 1994;331:489-495.
3. Chesebro JH, Badimon L, Fuster V. Importance of antithrombin therapy during coronary angioplasty. J Am Coll Cardiol 1991; 17: 96B-100B.
4. Baykal D, Schmedtje JF Jr, Runge MS. Role of the thrombin receptor in restenosis and atherosclerosis. Am J Cardiol 1995;75:82B-87B.
5. Anonymous. Dissolution/physical Tests: the United States Phamacopeia the National Formulary. US Pharmacopeial Convention 1990;711:1578-1579.
6. van der Geest RJ, Morris KG, Cusma JT, Reiber JH. Postmortem validation of the automated coronary analysis (ACA) software package. Int J Card Imaging 1994;10:95-102.
7. Dewanjee MK, Tago M, Josa M, Fuster V, Kaye MP. Quantification of platelet retention in aortocoronary femoral vein bypass graft in dogs treated with dipyridamole and aspirin. Circulation 1984;69:350-356.
8. Tanguay JF, Crowley JJ, Kruse KK, Armstrong BA, Santos RM, Zidar JP, Phillips HR, Stack RS. Antiplatelet vs. warfarin therapy: platelet, neutrophil and thrombus deposition in a porcine coronary artery model. J Interventional Card 1997;10:349-356.
9. Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circ Res 1980;47:1-9.
10. Riessen R, Isner JM. Prospects for site-specific delivery of pharmacologic and molecular therapies. J Am Coll Cardiol 1994; 23:1234-1244.
11. Kikumoto R, Tamao Y, Tezuka T, Tonomura S, Hara H, Ninomiya K, Hijikata A, Okamoto S. Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl+++) sulfonyl]-l-arginyl)]-2-piperidinecarboxylic acid. Biochemistry 1984;23:85-90.
12. Jang IK, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 1990;81:219-225.
13. Meyer BJ, Fernandez-Ortiz A, Mailhac A, Falk E, Badimon L, Michael AD, Chesebro JH, Fuster V, Badimon JJ. Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty. Circulation 1994;90:2474-2480.
14. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989;79:657-665.
15. Lam JY, Chesebro JH, Steele PM, Heras M, Webster MW, Badimon L, Fuster V. Antithrombotic therapy for deep arterial injury by angioplasty. Efficacy of common platelet inhibition compared with thrombin inhibition in pigs. Circulation 1991;84:814-820.
16. Buchwald AB, Sandrock D, Unterberg C, Ebbecke M, Nebendahl K, Luders S, Munz DL, Wiegand V. Platelet and fibrin deposition on coronary stents in minipigs: effect of hirudin versus heparin. J Am Coll Cardiol 1993;21:249-254.
17. Serruys PW, Herrman JP, Simon R, Rutsch W, Bode C, Laarman GJ, van Dijk R, van den Bos AA, Umans VA, Fox KA, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty: Helvetica Investigators. N Engl J Med 1995;333:757-763.
18. Anonymous. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes: the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. N Engl J Med 1996;335:775-782.
19. Antman EM. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 1994;90:1624-1630.
20. Anonymous. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes: the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Circulation 1994;90:1631-1637.
21. Neuhaus KL, von Essen R, Tebbe U, Jessel A, Heinrichs H, Maurer W, Doring W, Harmjanz D, Kotter V, Kaihammer E, et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study: a study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK). Circulation 1994;90:1638-1642.
22. Edelman ER, Rogers C. Hoop dreams: stents without restenosis. Circulation 1996;94:1199-1202.